Market capitalization | $8.28b |
Enterprise Value | $10.01b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 134.34 |
EV/Sales (TTM) EV/Sales | 3.63 |
P/S ratio (TTM) P/S ratio | 3.00 |
P/B ratio (TTM) P/B ratio | 3.44 |
Revenue growth (TTM) Revenue growth | 10.37% |
Revenue (TTM) Revenue | $2.76b |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
29 Analysts have issued a Exact Sciences Corporation forecast:
29 Analysts have issued a Exact Sciences Corporation forecast:
Dec '24 |
+/-
%
|
||
Revenue | 2,759 2,759 |
10%
10%
|
|
Gross Profit | 1,911 1,911 |
9%
9%
|
|
EBITDA | 14 14 |
119%
119%
|
EBIT (Operating Income) EBIT | -200 -200 |
34%
34%
|
Net Profit | -1,029 -1,029 |
404%
404%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
Head office | United States |
CEO | Kevin Conroy |
Employees | 7,000 |
Founded | 1995 |
Website | www.exactsciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.